{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:52Z","timestamp":1793946532340,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015498","name":"Yale School of Management","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015498","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eclinm.2026.104234","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:44:01Z","timestamp":1790606641000},"page":"104234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and efficacy of SOM3355 in patients with Huntington\u2019s disease (SOMCT03): a phase 2b, randomised, placebo-controlled, multicentre, dose-ranging study"],"prefix":"10.1016","volume":"100","author":[{"given":"Jaime","family":"Kulisevsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Craufurd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lewerenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesa","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Squitieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6055-2614","authenticated-orcid":false,"given":"Katia","family":"Youssov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5874-9204","authenticated-orcid":false,"given":"Jean-Marc","family":"Burgunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Ferr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Panigone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Medori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eclinm.2026.104234_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.nurt.2008.01.008","article-title":"Symptomatic treatment of Huntington disease","volume":"5","author":"Adam","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104234_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104234_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073845","article-title":"Huntington\u2019s disease: complex pathogenesis and therapeutic strategies","volume":"25","author":"Tong","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104234_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington\u2019s disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.eclinm.2026.104234_bib5","series-title":"Handbook of clinical neurology","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/B978-0-444-63916-5.00016-1","article-title":"Gait, balance, and falls in Huntington disease","volume":"vol. 159","author":"Vuong","year":"2018"},{"key":"10.1016\/j.eclinm.2026.104234_bib6","series-title":"Movement disorders. Brain\u2019s diseases of the nervous system","first-page":"412","author":"Harding","year":"1993"},{"key":"10.1016\/j.eclinm.2026.104234_bib7","series-title":"Principles and practice of movement disorders","first-page":"311","article-title":"Huntington disease","author":"Fahn","year":"2011"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104234_bib8","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1007\/s00415-023-11804-0","article-title":"Measuring cognitive impairment and monitoring cognitive decline in Huntington\u2019s disease: a comparison of assessment instruments","volume":"270","author":"Horta-Barba","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.eclinm.2026.104234_bib9","article-title":"Observing Huntington\u2019s disease: the European Huntington\u2019s disease Network\u2019s REGISTRY","volume":"2","author":"Orth","year":"2010","journal-title":"PLoS Curr"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104234_bib10","article-title":"Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104234_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/mdc3.12706","article-title":"Comparing risperidone and olanzapine to tetrabenazine for the management of Chorea in Huntington disease: an analysis from the Enroll-HD database","volume":"6","author":"Schultz","year":"2019","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104234_bib12","first-page":"69","article-title":"Short-term effects of olanzapine in Huntington disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"issue":"21","key":"10.1016\/j.eclinm.2026.104234_bib13","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of huntingtons disease: an Evidence- based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104234_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10401230701844802","article-title":"Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington\u2019s disease","volume":"20","author":"Duff","year":"2008","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.eclinm.2026.104234_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2013.00114","article-title":"Dopamine imbalance in Huntington\u2019s disease: a mechanism for the lack of behavioral flexibility","volume":"7","author":"Chen","year":"2013","journal-title":"Front Neurosci"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104234_bib16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1176\/jnp.17.4.496","article-title":"Depression and stages of Huntington\u2019s disease","volume":"17","author":"Paulsen","year":"2005","journal-title":"J Neuropsychiatr"},{"key":"10.1016\/j.eclinm.2026.104234_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2016.02.008","article-title":"Neuropsychiatric symptoms are very common in premanifest and early stage Huntington\u2019s Disease","volume":"25","author":"Martinez-Horta","year":"2016","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.eclinm.2026.104234_bib18","series-title":"XENAZINE (tetrabenazine) tablets, for oral use","year":"2008"},{"key":"10.1016\/j.eclinm.2026.104234_bib19","series-title":"Approval Package: NDA 216354 (AUSTEDO XR\/deutetrabenazine)","year":"2023"},{"key":"10.1016\/j.eclinm.2026.104234_bib20","series-title":"Approval Package: NDA 208082 (AUSTEDO\/deutetrabenazine)","year":"2017"},{"key":"10.1016\/j.eclinm.2026.104234_bib21","series-title":"Approval Package: NDA 209241 (INGREZZA\/valbenazine)","year":"2017"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104234_bib22","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/bcp.15635","article-title":"A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington\u2019s disease","volume":"89","author":"Gamez","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104234_bib23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104234_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with huntington disease: a randomized clinical trial","volume":"316","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104234_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Stimming","year":"2023","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104234_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JHD-210519","article-title":"Social withdrawal in Huntington\u2019s disease: a scoping review","volume":"11","author":"Gibson","year":"2022","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.eclinm.2026.104234_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1824708","article-title":"SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and \u03b21-adrenergic antagonism for the treatment of movement and neuropsychiatric disorders","volume":"17","author":"Turilli-Ghisolfi","year":"2026","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104234_bib28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/jnnp.72.6.726","article-title":"Autonomic nervous system function in Huntington\u2019s disease","volume":"72","author":"Andrich","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104234_bib29","first-page":"1520","article-title":"Natural history of Huntington disease","volume":"70","author":"Dorsey","year":"2013","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104234_bib30","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1600-0404.2009.01251.x","article-title":"Autonomic dysfunction in presymptomatic and early symptomatic Huntington\u2019s disease","volume":"121","author":"Kobal","year":"2010","journal-title":"Acta Neurol Scand"},{"issue":"September 2020","key":"10.1016\/j.eclinm.2026.104234_bib31","article-title":"Autonomic dysregulation as an early pathologic feature of Huntington disease","volume":"231","author":"Schultz","year":"2021","journal-title":"Auton Neurosci Basic Clin"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104234_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/braincomms\/fcac253","article-title":"Autonomic changes in Huntington\u2019s disease correlate with altered central autonomic network connectivity","volume":"4","author":"Schultz","year":"2022","journal-title":"Brain Commun"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:47:43Z","timestamp":1793944063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026004876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"alternative-id":["S2589537026004876"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104234","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of SOM3355 in patients with Huntington\u2019s disease (SOMCT03): a phase 2b, randomised, placebo-controlled, multicentre, dose-ranging study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104234"}}